MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: HIV/AIDS
HIV/AIDS

A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7

MedXY Editorial TeamNov 12, 2025
HIVpneumococcal vaccine

Highlights

– V116, a 21‑valent adult‑specific pneumococcal conjugate vaccine, elicited measurable opsonophagocytic activity (OPA) responses against all 21 vaccine serotypes in adults living with HIV.

– For the 13 serotypes shared with PCV15 and PPSV23, V116 responses at day 30 were generally similar to responses after PCV15 followed by PPSV23 at week 12; for the eight serotypes unique to V116, responses were higher than the comparator regimen.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Next-Day HIV Viral Load Results Improve Time to Care for People Living with HIV but Show Limited Impact on Prevention Linkage

HIV/AIDSDec 21, 2025

High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action

HIV/AIDSNov 29, 2025

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

HIV/AIDSNov 12, 2025
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story